Skip to main content

Table 1 The baseline characteristics of included studies

From: Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Author Year Publication type Source of analyzed data Country Cancer type Sample size Immunotherapy regimen BMI stratification Outcomes
Ichihara (cohort 1) 2020 Full text Retrospective cohort Japan NSCLC 84 Cohort1: pembrolizumab High: ≥ 22.0; low: < 22.0 OS, PFS
Ichihara (Cohort 2) 2020 Full text Retrospective cohort Japan NSCLC 429 Cohort2: nivolumab, pembrolizumab, atezolizumab High: ≥ 22.0; low: < 22.0 OS, PFS
Popinat 2019 Full text Retrospective cohort France NSCLC 55 Nivolumab High: ≥ 24.7; low: < 24.7 OS
Magri 2019 Full text Retrospective cohort Israel NSCLC 46 Nivolumab High: ≥ 24.6; low: < 24.6 OS
Kulkarni 2019 Abstract Retrospective cohort USA NSCLC 148 Nivolumab High: ≥ 25.0; low: < 25.0 OS, PFS
Kichenadasse 2019 Full text NCT02031458 NCT01846416 USA, Australia NSCLC 1434 Atezolizumab Normal: 18.5–24.9 overweight: 25.0–29.9 obese: ≥ 30 OS, PFS, IRAEs
Zhi 2018 Abstract Retrospective cohort USA NSCLC 703 Nivolumab, pembrolizumab Normal: 18.5–24.9; overweight: 25.0–29.9; obese: ≥ 30 OS, PFS
Wang 2019 Full text Retrospective cohort USA NSCLC Melanoma OC 250 PD-L1 inhibitor High: ≥ 30; low: < 30 OS, PFS
Cortellini 2019 Full text Retrospective cohort Italy NSCLC RCC melanoma 976 Pembrolizumab, nivolumab, atezolizumab Definition1: high: ≥ 25.0; low: < 25.0 definition2: Normal: 18.5–24.9; overweight: 25·0–29.9; Obese: ≥ 30 OS, PFS, IRAEs
Naik 2019 Full text Retrospective cohort USA Melanoma 139 PD-1 inhibitor High: 25.0–35 low: < 25 OS, PFS
Richtig 2018 Full text Retrospective cohort Austria Melanoma 76 Ipilimumab High: ≥ 25.0; Low: < 25.0 OS, PFS
McQuade (cohort 1) 2018 Full text NCT00324155& retrospective corhot USA, Australia Melanoma 207 Cohort 1:
Ipilimumab plus dacarbazine
Normal: 18.5–24.9; overweight: 25.0–29.9; Obese: ≥ 30 OS, PFS, IRAEs
McQuade (Cohort 2) 2018 Full text NCT00324155& Retrospective corhot USA, Australia Melanoma 329 Cohort 2: Pembrolizumab, nivolumab, atezolizumab Normal: 18.5–24.9; Overweight: 25.0–29.9; Obese: ≥ 30 OS, PFS, IRAEs
Labadie 2019 Full text Retrospective cohort USA, Canada, Spain RCC 90 Pembrolizumab, nivolumab, atezolizumab Normal: 18.5–24.9
Overweight: 25.0–29.9 Obese: ≥ 30
OS, PFS
De Giorgi 2019 Full text Retrospective cohort Italy RCC 313 Nivolumab high: ≥ 25.0; low: < 25.0 OS
  1. NSCLC, non-small cell lung cancer; RCC, renal cell cancer; OC, ovarian cancer; BMI, Body mass index; OS, overall survival; PFS, progression-free survival; IRAEs, immune-related adverse effects